CTRI/2014/08/004841招募中未知
An Open Label, Single Center Study to assess the effect of IminoNorm on the Glycaemic index of common carbohydrates
Phynova Group0 个研究点目标入组 12 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Healthy Volunteers with a BMI between 18 and 25
- •Non-Diabetic or any pre-diabetic conditions demonstrated by a fasting blood sugar between 3.9 to 5.5 mmols/L (70 - 100mg/dL).Not on any diabetic or insulin resistance medication
排除标准
- •Abnormal laboratory values at screening.
- •Pregnant or Lactating women
- •Subjects with any cardio-vascular diseases
- •Subjects otherwise judged by the PI not fit to participate in the study
- •Any past significant medical history
- •Any Psychiatric disorder or on any such medications
- •Any malignancy or history of malignancies
- •Any known hypersensitivity or allergy
- •Recent participation (within the last 3 months) in any other clinical trial
研究者
相似试验
进行中（未招募）
不适用
An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the combination of valsartan 160 mg plus amlodipine 5 mg in hypertensive patients not adequately responding to a 4 week treatment with amlodipine 5 mg or felodipine 5 mg in monotherapy - ExPress - Mmoderate essential hypertensionMedDRA version: M15Level: LLTClassification code 10015488EUCTR2006-001484-39-DEovartis Pharma GmbH230
进行中（未招募）
不适用
An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequately responding to a 4 week therapy with the free combination of an angiotensin receptor blocker (candersartan 32 mg) plus HCTZ 25 mg - CICEROEUCTR2006-001311-30-DEovartis Pharma GmbH220
进行中（未招募）
1 期
A study to to evaluate the efficacy, safety and tolerability of PDNO (nitrosooxypropanol) infusion in COVID-19 patients with high blood pressure in lung arteries.Acute pulmonary hypertension during COVID-19 infectionMedDRA version: 20.0Level: HLTClassification code 10037401Term: Pulmonary hypertensionsSystem Organ Class: 100000004855EUCTR2020-002982-33-SEAttgeno AB16
进行中（未招募）
不适用
An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately responding to a 5 week therapy with ramipril 5 mg and felodipine 5 mgPatients with essential hypertensionMedDRA version: M15Level: LLTClassification code 10015488EUCTR2005-003976-39-DEovartis Pharma GmbH200
进行中（未招募）
不适用
An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the single pill (SPC) combination of Aliskiren 300 mg / Amlodipine 10 mg in hypertensive patients not adequately respond to an uptitrated 4 week therapy with the SPC of Olmesartan 40 mg / Amlodipine 10 mg, with a potential extention if patients still not adequately respond with a 4 week therapy with the SPC Aliskiren 300 mg / Amlodipine 10 mg / HCTZ 12,5 mg - AWESOMEessential hypertensionMedDRA version: 12.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2009-016693-33-DEovartis Pharma GmbH